Lumitron Technologies

About Lumitron Technologies

Lumitron Technologies, founded in 2018 by Maurie Stang and Dr. Chris Barty, is an Irvine, California-based company operating in the medical diagnostic equipment industry. The firm is focused on commercializing a new generation of X-ray technology that originated from nearly two decades and over $220 million of federally funded research at Lawrence Livermore National Laboratory (LLNL). Dr. Barty, the company's CTO, was instrumental in inventing the core technologies during his 17-year tenure at LLNL, where he was the CTO for the National Ignition Facility and Photon Science Directorate. His extensive background in applied physics, with degrees from Stanford University and multiple honors, underpins the company's scientific foundation. Maurie Stang, the Executive Chairman, brings a strong track record of founding and leading successful international companies in the healthcare and technology sectors.

Lumitron is developing the HyperVIEW™ platform, a laser-Compton X-ray source designed to replicate the power of a football-field-sized synchrotron particle accelerator in a device comparable in size to a modern CT or MRI machine. This technology represents a significant shift from conventional X-ray systems, which have remained fundamentally unchanged for over 120 years. The system works by colliding a high-energy electron beam with a laser beam to produce monochromatic, high-brilliance X-rays. This enables imaging with unprecedented detail, potentially up to 1,000 times higher resolution, while simultaneously allowing for a dose reduction of up to 100 times compared to current standards.

The company's business model centers on the development and manufacturing of these advanced X-ray systems for both medical and industrial applications. In the healthcare sector, Lumitron serves hospitals and clinical research institutes, aiming to provide a 'theranostics' machine capable of both diagnosing and treating diseases like cancer at a cellular level, simultaneously. This could enable precision radiotherapy, such as FLASH therapy, and significantly improve soft tissue imaging. For industrial clients in fields like aerospace, additive manufacturing, and security, the technology offers non-destructive material analysis and inspection with high precision. Having secured exclusive commercial rights to the technology from LLNL, the company has raised $34 million in a Series C funding round and is establishing its R&D and manufacturing facility at the University of California, Irvine's research park.